# Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients

> **NCT00195533** · — · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 801 (actual)

## Conditions studied

- Hematological Malignancy
- Leukemia
- Myelodysplasia
- Lymphoma
- Myeloma
- Stem Cell Transplantation

## Interventions

- **DRUG:** piperacillin-tazobactam
- **DRUG:** glycopeptide

## Key facts

- **NCT ID:** NCT00195533
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2001-07
- **Primary completion:** 2005-03
- **Final completion:** 2005-03
- **Target enrollment:** 801 (ACTUAL)
- **Last updated:** 2009-11-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00195533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00195533, "Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00195533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*